Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Spontaneous "pneumo-apoplexy" as a presentation of pituitary adenoma.

Singhal A, Gohlke PR, Chapman PR.

Clin Imaging. 2019 Jul 23;58:152-155. doi: 10.1016/j.clinimag.2019.07.005. [Epub ahead of print]

PMID:
31376705
2.

Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?

Culman J, Jacob T, Schuster SO, Brolund-Spaether K, Brolund L, Cascorbi I, Zhao Y, Gohlke P.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Sep;390(9):949-959. doi: 10.1007/s00210-017-1395-y. Epub 2017 Jul 2.

PMID:
28669009
3.

Mitochondrial uncoupling proteins regulate angiotensin-converting enzyme expression: crosstalk between cellular and endocrine metabolic regulators suggested by RNA interference and genetic studies.

Dhamrait SS, Maubaret C, Pedersen-Bjergaard U, Brull DJ, Gohlke P, Payne JR, World M, Thorsteinsson B, Humphries SE, Montgomery HE.

Bioessays. 2016 Jul;38 Suppl 1:S107-18. doi: 10.1002/bies.201670909.

PMID:
27417115
4.

Mitochondrial uncoupling proteins regulate angiotensin-converting enzyme expression: crosstalk between cellular and endocrine metabolic regulators suggested by RNA interference and genetic studies.

Dhamrait SS, Maubaret C, Pedersen-Bjergaard U, Brull DJ, Gohlke P, Payne JR, World M, Thorsteinsson B, Humphries SE, Montgomery HE.

Inside Cell. 2016 Jan;1(1):70-81. Epub 2015 Aug 2.

5.

Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.

Schmedt Auf der Günne W, Zhao Y, Hedderich J, Gohlke P, Culman J.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Sep;388(9):939-51. doi: 10.1007/s00210-015-1126-1. Epub 2015 May 8.

PMID:
25953200
6.

Practical anatomy of the central skull base region.

Chapman PR, Bag AK, Tubbs RS, Gohlke P.

Semin Ultrasound CT MR. 2013 Oct;34(5):381-92. doi: 10.1053/j.sult.2013.08.001. Review.

PMID:
24216449
7.

Treatment of rats with pioglitazone in the reperfusion phase of focal cerebral ischemia: a preclinical stroke trial.

Culman J, Nguyen-Ngoc M, Glatz T, Gohlke P, Herdegen T, Zhao Y.

Exp Neurol. 2012 Dec;238(2):243-53. doi: 10.1016/j.expneurol.2012.09.003. Epub 2012 Sep 17.

PMID:
22995601
8.

Activation of cerebral peroxisome proliferator-activated receptors γ (PPARγ) reduces neuronal damage in the substantia nigra after transient focal cerebral ischaemia in the rat.

Zuhayra M, Zhao Y, von Forstner C, Henze E, Gohlke P, Culman J, Lützen U.

Neuropathol Appl Neurobiol. 2011 Dec;37(7):738-52. doi: 10.1111/j.1365-2990.2011.01169.x.

PMID:
21366664
9.

Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain.

Glatz T, Stöck I, Nguyen-Ngoc M, Gohlke P, Herdegen T, Culman J, Zhao Y.

J Hypertens. 2010 Jul;28(7):1488-97. doi: 10.1097/HJH.0b013e3283396e4e.

PMID:
20410836
10.

The receptor tyrosine kinase MerTK regulates dendritic cell production of BAFF.

Gohlke PR, Williams JC, Vilen BJ, Dillon SR, Tisch R, Matsushima GK.

Autoimmunity. 2009 Mar;42(3):183-97. doi: 10.1080/08916930802668586.

11.

Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia.

Patzer A, Zhao Y, Stöck I, Gohlke P, Herdegen T, Culman J.

Eur J Neurosci. 2008 Nov;28(9):1786-94. doi: 10.1111/j.1460-9568.2008.06478.x.

PMID:
18973594
12.

Haplotype of growth hormone and angiotensin I-converting enzyme genes, serum angiotensin I-converting enzyme and ventricular growth: pathway inference in pharmacogenetics.

Huang S, Chen XH, Payne JR, Pennell DJ, Gohlke P, Smith MJ, Day IN, Montgomery HE, Gaunt TR.

Pharmacogenet Genomics. 2007 Apr;17(4):291-4.

PMID:
17496728
13.

PPAR-gamma: therapeutic target for ischemic stroke.

Culman J, Zhao Y, Gohlke P, Herdegen T.

Trends Pharmacol Sci. 2007 May;28(5):244-9. Epub 2007 Apr 9. Review.

PMID:
17416424
14.

Lack of change in serum angiotensin-converting enzyme activity during the menstrual cycle.

Sanders J, Harris J, Cooper J, Gohlke P, Humphries SE, Montgomery H, Woods DR.

J Renin Angiotensin Aldosterone Syst. 2006 Dec;7(4):231-5.

PMID:
17318793
15.

The impact of ACE genotype on serum ACE activity in a black South African male population.

Payne JR, Dhamrait SS, Gohlke P, Cooper J, Scott RA, Pitsiladis YP, Humphries SE, Rayner B, Montgomery HE.

Ann Hum Genet. 2007 Jan;71(Pt 1):1-7.

16.

Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.

Brdon J, Kaiser S, Hagemann F, Zhao Y, Culman J, Gohlke P.

J Hypertens. 2007 Jan;25(1):187-96.

PMID:
17143191
17.

No correlation between circulating ACE activity and VO2max or mechanical efficiency in women.

Day SH, Gohlke P, Dhamrait SS, Williams AG.

Eur J Appl Physiol. 2007 Jan;99(1):11-8. Epub 2006 Sep 28.

PMID:
17006710
19.

Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats.

Odenwald T, Nakagawa K, Hadtstein C, Roesch F, Gohlke P, Ritz E, Schaefer F, Schmitt CP.

J Am Soc Nephrol. 2006 Mar;17(3):655-62. Epub 2006 Jan 18.

20.

Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats.

Xu J, Scholz A, Rösch N, Blume A, Unger T, Kreutz R, Culman J, Gohlke P.

J Hypertens. 2005 Dec;23(12):2277-85.

PMID:
16269970
21.

The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain.

Zhao Y, Patzer A, Gohlke P, Herdegen T, Culman J.

Eur J Neurosci. 2005 Jul;22(1):278-82.

PMID:
16029218
22.

No association between Angiotensin Converting Enzyme (ACE) gene variation and endurance athlete status in Kenyans.

Scott RA, Moran C, Wilson RH, Onywera V, Boit MK, Goodwin WH, Gohlke P, Payne J, Montgomery H, Pitsiladis YP.

Comp Biochem Physiol A Mol Integr Physiol. 2005 Jun;141(2):169-75.

PMID:
15950509
23.

Circulating angiotensin converting enzyme activity is correlated with muscle strength.

Williams AG, Day SH, Folland JP, Gohlke P, Dhamrait S, Montgomery HE.

Med Sci Sports Exerc. 2005 Jun;37(6):944-8.

PMID:
15947718
24.
25.

The acute effects of exercise and glucose ingestion on circulating angiotensin-converting enzyme in humans.

Day SH, Williams C, Folland JP, Gohlke P, Williams AG.

Eur J Appl Physiol. 2004 Aug;92(4-5):579-83.

PMID:
15048577
26.

Short-term effects of exogenous angiotensin II on plasma fibrinolytic balance in normal subjects.

Lottermoser K, Hertfelder HJ, Gohlke P, Vetter H, Düsing R.

Clin Exp Hypertens. 2004 Jan;26(1):13-26.

PMID:
15000294
27.

Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats.

Groth W, Blume A, Gohlke P, Unger T, Culman J.

J Hypertens. 2003 Nov;21(11):2175-82.

PMID:
14597862
28.

The serum angiotensin-converting enzyme and angiotensin II response to altered posture and acute exercise, and the influence of ACE genotype.

Woods D, Sanders J, Jones A, Hawe E, Gohlke P, Humphries SE, Payne J, Montgomery H.

Eur J Appl Physiol. 2004 Mar;91(2-3):342-8. Epub 2003 Nov 1.

PMID:
14595564
29.

Candesartan cilexetil: development and preclinical studies.

Gohlke P, Jürgensen T, von Kügelgen S, Unger T.

Drugs Today (Barc). 1999 Feb;35(2):105-15.

PMID:
12973413
30.

Measurement of plasma endothelin-1 in experimental hypertension and in healthy subjects.

Abdel-Sayed S, Nussberger J, Aubert JF, Gohlke P, Brunner HR, Brakch N.

Am J Hypertens. 2003 Jul;16(7):515-21.

PMID:
12850383
31.

Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.

Lottermoser K, Unger T, Gohlke P, Vetter H, Düsing R.

Am J Hypertens. 2003 Jun;16(6):445-52.

PMID:
12799092
32.

Angiotensin II and the fibroproliferative response to acute lung injury.

Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, McAnulty RJ, Laurent GJ.

Am J Physiol Lung Cell Mol Physiol. 2004 Jan;286(1):L156-64. Epub 2003 May 16.

33.

Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells.

Zhao Y, Biermann T, Luther C, Unger T, Culman J, Gohlke P.

J Neurochem. 2003 May;85(3):759-67.

34.

Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death.

Xu J, Culman J, Blume A, Brecht S, Gohlke P.

Stroke. 2003 May;34(5):1287-92. Epub 2003 Apr 3.

PMID:
12677021
35.

Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats.

Pees C, Unger T, Gohlke P.

Int J Biochem Cell Biol. 2003 Jun;35(6):963-72.

PMID:
12676180
36.

The renin-angiotensin system in the brain: possible therapeutic implications for AT(1)-receptor blockers.

Culman J, Blume A, Gohlke P, Unger T.

J Hum Hypertens. 2002 Aug;16 Suppl 3:S64-70. Review.

37.

Lymphopenia in the BB rat model of type 1 diabetes is due to a mutation in a novel immune-associated nucleotide (Ian)-related gene.

MacMurray AJ, Moralejo DH, Kwitek AE, Rutledge EA, Van Yserloo B, Gohlke P, Speros SJ, Snyder B, Schaefer J, Bieg S, Jiang J, Ettinger RA, Fuller J, Daniels TL, Pettersson A, Orlebeke K, Birren B, Jacob HJ, Lander ES, Lernmark A.

Genome Res. 2002 Jul;12(7):1029-39.

38.

Peripherally applied candesartan inhibits central responses to angiotensin II in conscious rats.

Gohlke P, Kox T, Jürgensen T, von Kügelgen S, Rascher W, Unger T, Culman J.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Jun;365(6):477-83. Epub 2002 Apr 5.

PMID:
12070762
39.

Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats.

Gohlke P, Von Kügelgen S, Jürgensen T, Kox T, Rascher W, Culman J, Unger T.

J Hypertens. 2002 May;20(5):909-18.

PMID:
12011652
40.

Role of neutral endopeptidase and angiotensin-converting enzyme in deoxycorticosterone acetate-salt hypertension.

Gohlke P.

J Hypertens. 2002 May;20(5):821-3. Review. No abstract available.

PMID:
12011635
41.

AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats.

Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T.

J Pharmacol Exp Ther. 2001 Jul;298(1):62-70.

PMID:
11408526
42.

At receptor inhibition affects the noradrenaline sensitivity in isolated portal vein of normotensive rat.

Datté JY, Gohlke P, Pees C, Ziegler A.

Clin Exp Hypertens. 2001 Apr;23(3):177-87.

PMID:
11339685
43.

Significance of timing of angiotensin AT1 receptor blockade in rats with myocardial infarction-induced heart failure.

Xia QG, Chung O, Spitznagel H, Illner S, Jänichen G, Rossius B, Gohlke P, Unger T.

Cardiovasc Res. 2001 Jan;49(1):110-7.

PMID:
11121802
44.

Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.

Bishop JE, Kiernan LA, Montgomery HE, Gohlke P, McEwan JR.

Cardiovasc Res. 2000 Jul;47(1):57-67.

PMID:
10869530
46.

Effects of a novel angiotensin AT(1) receptor antagonist, HR720, on rats with myocardial infarction.

Xia QG, Chung O, Spitznagel H, Sandmann S, Illner S, Rossius B, Jähnichen G, Reinecke A, Gohlke P, Unger T.

Eur J Pharmacol. 1999 Dec 3;385(2-3):171-9.

PMID:
10607873
47.

Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats.

Tschöpe C, Reinecke A, Seidl U, Yu M, Gavriluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T.

Am J Physiol. 1999 Dec;277(6):H2333-40. doi: 10.1152/ajpheart.1999.277.6.H2333.

PMID:
10600853
48.

Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence.

Unger T, Culman J, Gohlke P.

J Hypertens Suppl. 1998 Sep;16(7):S3-9. Review.

PMID:
9855025
49.

Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.

Montgomery HE, Kiernan LA, Whitworth CE, Fleming S, Unger T, Gohlke P, Mullins JJ, McEwan JR.

J Hypertens. 1998 May;16(5):635-43.

PMID:
9797175
50.

Angiotensin AT2 receptor degradation is prevented by ligand occupation.

Csikós T, Balmforth AJ, Grojec M, Gohlke P, Culman J, Unger T.

Biochem Biophys Res Commun. 1998 Feb 4;243(1):142-7.

PMID:
9473495

Supplemental Content

Loading ...
Support Center